Publicaciones en colaboración con investigadores/as de Consiglio Nazionale delle Ricerche (19)

2023

  1. Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

    Journal of neuroinflammation, Vol. 20, Núm. 1, pp. 108

2018

  1. Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB1 receptor ligand antagonists

    Bioorganic and Medicinal Chemistry, Vol. 26, Núm. 1, pp. 295-307

2016

  1. Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome

    Pharmacology Research and Perspectives, Vol. 4, Núm. 2

2015

  1. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders

    Journal of Neuroimmune Pharmacology, Vol. 10, Núm. 2, pp. 233-244

2014

  1. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

    Epilepsia, Vol. 55, Núm. 6, pp. 791-802

2013

  1. Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors

    Multiple Sclerosis Journal, Vol. 19, Núm. 14, pp. 1896-1904

  2. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: A potential role of cyclooxygenase-2-dependent metabolism of 2-AG

    Cell Death and Disease, Vol. 4, Núm. 10

2009

  1. Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas

    Drug and Alcohol Dependence, Vol. 99, Núm. 1-3, pp. 354-358

2005

  1. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease

    Brain Research, Vol. 1050, Núm. 1-2, pp. 210-216

  2. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis

    Neurobiology of Disease, Vol. 20, Núm. 2, pp. 207-217

  3. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels

    Biochemical Pharmacology, Vol. 70, Núm. 3, pp. 446-452

2004

  1. Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse

    British Journal of Pharmacology, Vol. 143, Núm. 4, pp. 455-464

2003

  1. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease

    Journal of Neurochemistry, Vol. 84, Núm. 5, pp. 1097-1109

2002

  1. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine

    Brain Research, Vol. 954, Núm. 1, pp. 73-81

2001

  1. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues

    European Journal of Pharmacology, Vol. 420, Núm. 2-3, pp. 123-131

2000

  1. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of Δ9- tetrahydrocannabinol-tolerant rats

    Journal of Neurochemistry, Vol. 74, Núm. 4, pp. 1627-1635

  2. Sex steroid influence on cannabinoid CB1 receptor mRNA and endocannabinoid levels in the anterior pituitary gland

    Biochemical and Biophysical Research Communications, Vol. 270, Núm. 1, pp. 260-266

1999

  1. Brain regional distribution of endocannabinoids: Implications for their biosynthesis and biological function

    Biochemical and Biophysical Research Communications, Vol. 256, Núm. 2, pp. 377-380

  2. Identification of endocannabinoids and cannabinoid CB1 receptor mRNA in the pituitary gland

    Neuroendocrinology, Vol. 70, Núm. 2, pp. 137-145